Page 108 - Drug Class Review
P. 108
Page 84 of 205
Drug Effectiveness Review Project
total (n = 468) 71.3 52 97 18.5 0.6 27.5
placebo placebo; placebo/20 mg/d 71; 71.6 49; 59 91; 99 18.2; 18.8 0.5; 0.6 28.1; 27 Secondary Outcome Measures: ADAS-Noncog; ADAS total score; MMSE; caregiver-rated CGIC; Significantly better PDS score only for TAC 40 mg/d compared to placebo (P = 0.046) Significant improvement in ADAS-Cog and CGIC at 12 weeks for TAC compared to placebo only No significant differences in ADAS-Noncog or MMSE at 12 weeks Significantly greater improvement in ADAS total score only for 80 mg/d TAC (P = 0.029) Significantly greater improvement in caregiver-rated CGIC for TAC 40 mg/d a
Alzheimer classification: Mild-moderate
Groups similar at baseline: Yes
tacrine 20; 40; 60; 80 mg/d 70.7; 71.9; 72.1; 70.8 49; 50; 55; 47 97; 97; 96; 99 18.8, 18.4, 17.9, 19.2 0.8, 0.5, 0.7, 0.6 27, 28.4, 27.7, 26.6 Primary Outcome Measures: ADAS-Cog; CGIC Timing of assessments: Weeks 4, 6, 10 and 12 Health Outcome Measures: Intermediate Outcome Measures: (observed cases) for 80 mg/d (P = 0.015 for both)*
PDS • • • • •
Final Report Update 1 Authors: Farlow et al. Year: 1992 POPULATION CHARACTERISTICS: Mean age (years): Sex (% female): Ethnicity: (% white) Other germane population qualities: MMSE • HIS • ADAS-Cog • OUTCOME ASSESSMENT: RESULTS: Alzheimer's Drugs
